MetaADEDB 2.0 @ LMMD
Betaxolol
(CHDPSNLJFOQTRK-UHFFFAOYSA-N)
Structure
SMILES
OC(COc1ccc(cc1)CCOCC1CC1)CNC(C)C.Cl
Molecular Formula:
C18H30ClNO3
Molecular Weight:
343.889
Log P:
3.5863
Hydrogen Bond Acceptor:
4
Hydrogen Bond Donor:
3
TPSA:
50.72
CAS Number(s):
63659-19-8; 72424-72-7
Synonym(s)
1.
Betaxolol
2.
ALO-1401-02
3.
Betaxolol Alcon
4.
Betaxolol Hydrochloride
5.
Betoptic
6.
Betoptima
7.
Kerlon
8.
Kerlone
9.
Oxodal
10.
SL-75212
11.
ALO 1401 02
12.
ALO140102
13.
Alcon, Betaxolol
14.
Hydrochloride, Betaxolol
15.
SL 75212
16.
SL75212
External Link(s)
MeSHD015784
PubChem Compound657296
45259220
107952
ChEBI643228
CHEMBLCHEMBL1691
KEGGdr:D00598
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Eye irritationFAERS: 6US FAERS
2Product quality issueFAERS: 5US FAERS
3Drug ineffectiveFAERS: 4US FAERS
4Incorrect dose administeredFAERS: 4US FAERS
5Eye painFAERS: 3US FAERS
6HeadacheFAERS: 3US FAERS
7Product dropper issueFAERS: 3US FAERS
8AnosmiaFAERS: 2US FAERS
9BlindnessFAERS: 2US FAERS
10CataractFAERS: 2US FAERS
11DeafnessFAERS: 2US FAERS
12DiplopiaFAERS: 2US FAERS
13Foreign body sensation in eyesFAERS: 2US FAERS
14GlaucomaFAERS: 2US FAERS
15MyalgiaFAERS: 2US FAERS
16PhotophobiaFAERS: 2US FAERS
17Abdominal discomfortFAERS: 1US FAERS
18Activities of daily living impairedFAERS: 1US FAERS
19AgeusiaFAERS: 1US FAERS
20AlopeciaFAERS: 1US FAERS
21AnhedoniaFAERS: 1US FAERS
22AstheniaFAERS: 1US FAERS
23AsthmaFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
24Cardiac ArrestFAERS: 1US FAERS
25Cardiac valve replacement complicationFAERS: 1US FAERS
26Depressed moodFAERS: 1US FAERS
27DizzinessFAERS: 1US FAERS
28Essential TremorFAERS: 1US FAERS
29Eye allergyFAERS: 1US FAERS
30Eye inflammationFAERS: 1US FAERS
31FatigueFAERS: 1US FAERS
32Feeling jitteryFAERS: 1US FAERS
33HypersensitivityFAERS: 1US FAERS
34HypersomniaFAERS: 1US FAERS
35HypogeusiaFAERS: 1US FAERS
36Impaired work abilityFAERS: 1US FAERS
37Instillation site painFAERS: 1US FAERS
38Instillation site pruritusFAERS: 1US FAERS
39Intestinal ObstructionFAERS: 1US FAERS
40Intraocular pressure test abnormalFAERS: 1US FAERS
41Liquid product physical issueFAERS: 1US FAERS
42MalaiseFAERS: 1US FAERS
43PalpitationsFAERS: 1US FAERS
44Product closure removal difficultFAERS: 1US FAERS
45Product package associated injuryFAERS: 1US FAERS
46Product packaging quantity issueFAERS: 1US FAERS
47Product physical consistency issueFAERS: 1US FAERS
48Product use complaintFAERS: 1US FAERS
49RadiculopathyFAERS: 1US FAERS
50RalesFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
51ShockFAERS: 1US FAERS
52Trisomy 21FAERS: 1US FAERS
53VertigoFAERS: 1US FAERS
54Visual ImpairmentFAERS: 1US FAERS
55WheezingFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.